Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Outcome and Risk Factors of Hodgkin Lymphoma Patients with Relapse or Progression After Autologous Stem Cell Transplant: A Report From the German Hodgkin Study Group (GHSG).

Bastian von Tresckow, MD, Horst Müller, PhD, Dennis A. Eichenauer, MD, Jan Peter Glossmann, MD, Andreas Josting, MD, Boris Böll, MD, Beate Klimm, MD, Michael Fuchs, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2012) 120 (21): 2633.

https://doi.org/10.1182/blood.V120.21.2633.2633

Published: 2012

Journal Articles

Late Events in Patients with Relapsed or Refractory Hodgkin’s Lymphoma Treated with an Autologous Stem Cell Transplantation.

Michal Sieniawski, MD, Andreas Josting, MD, Carmen Canals, MD, Anthony H. Goldstone, MD, Martin Gramatzki, MD, Didier Blaise, MD, Christian Gisselbrecht, MD, Charles Crawley, MD, Philippe Colombat, MD, Jean-Luc Harousseau, MD, Peter Johnson, MD, Angelo Michele Carella, MD, Anna Sureda, MD, Gerard Socie, MD, Norbert Schmitz, MD

Blood (2007) 110 (11): 834.

https://doi.org/10.1182/blood.V110.11.834.834

Published: 2007

Journal Articles

Prognostic Factors and Treatment Outcome in Lymphocyte Predominant and Classical Hodgkin’s Lymphoma: A Comprehensive Analysis of the German Hodgkin Study Group.

Lucia Nogova, MD, Thorsten Reineke, Corinne Brillant, Thomas Ruediger, Prof, Hans K. Mueller-Hermelink, Prof., Henning Bredenfeld, MD, Andreas Josting, MD, Rolf P. Mueller, Prof., Volker Diehl, Prof., Andreas Engert, Prof.

Blood (2006) 108 (11): 97.

https://doi.org/10.1182/blood.V108.11.97.97

Published: 2006

Journal Articles

Rituximab Added to an Intensified Salvage Chemotherapy Program Followed by Autologous Stem Cell Transplantation Improve in Relapsed and Refractory Aggressive Non-Hodgkin-Lymphoma.

Michal Sieniawski, MD, Jan-Peter Glossmann, MD, Thorsten Reineke, PhD, Volker Diehl, MD, Andreas Engert, MD, Andreas Josting, MD

Blood (2005) 106 (11): 1150.

https://doi.org/10.1182/blood.V106.11.1150.1150

Published: 2005

Journal Articles

A New BACOPP Schedule Is Feasible and Effective in Elderly Hodgkin’s Lymphoma Patients - Interim Results of a Multicenter Phase-II Trial of the German Hodgkin Study Group (GHSG).

Lucia Nogova, MD, Michal Sieniawski, MD, Hildrud Nisters-Backes, Veronika Jennissen, MD, Volker Diehl, MD, Andreas Engert, MD, Andreas Josting, MD

Blood (2005) 106 (11): 4735.

https://doi.org/10.1182/blood.V106.11.4735.4735

Published: 2005

Journal Articles

Outcome of Patients Progressing or Relapsing after Primary Treatment with Two Cycles of Chemotherapy and Radiotherapy for Early Stage (Favorable) Hodgkin’s Disease.

Andreas Josting, MD, Jeremy Franklin, PhD, Michal Sieniawski, MD, Beate Pfistner, PhD, Thomas Schober, Hildtrud Nisters-Backes, Andreas Engert, MD, Volker Diehl, MD

Blood (2005) 106 (11): 818.

https://doi.org/10.1182/blood.V106.11.818.818

Published: 2005

Journal Articles

Elderly Patients with Early-Unfavorable Stage Hodgkin’s Disease (HD) Have a Poorer Outcome When Treated with Combined Modality Treatment and Extended Field Radiotherapy (EF): A Retrospective Analysis of the German Hodgkin Study Group.

Andreas Engert, MD, Heinz Haverkamp, Hans T. Eich, MD, Andreas Josting, MD, Beate Pfistner, Volker Diehl

Blood (2004) 104 (11): 1305.

https://doi.org/10.1182/blood.V104.11.1305.1305

Published: 2004

Journal Articles

Cologne High-Dose Sequential Chemotherapy in Relapsed and Refractory Hodgkin Lymphoma - Results of a Large Multicenter Study of the German Hodgkin Lymphoma Study Group (GHSG).

Andreas Josting, MD, Christian Rudolph, MD, Markus Mapara, MD, Jan-Peter Glossmann, MD, Markus Sieber, MD, Hartmut H. Kirchner, MD, Bernd Dörken, MD, Dieter K. Hossfeld, MD, Jens Kisro, MD, Bernd Metzner, MD, Wolfgang E. Berdel, MD, Volker Diehl, MD, Andreas Engert, MD

Blood (2004) 104 (11): 309.

https://doi.org/10.1182/blood.V104.11.309.309

Published: 2004

Journal Articles

Comparison of Patients (Pts) Characteristic and Treatment Outcomes in Lymphocyte-Predominant (LPHD) and Classical Hodgkin’s Disease (cHD): A Report from the German Hodgkin Lymphoma Study Group (GHSG).

Lucia Nogova, MD, Thorsten Reineke, Andreas Josting, MD, Karolin Behringer, MD, Beate Pfistner, PhD, Volker Diehl, MD, Andreas Engert, MD

Blood (2004) 104 (11): 1309.

https://doi.org/10.1182/blood.V104.11.1309.1309

Published: 2004

Journal Articles

The Superior Prognosis of Female Patients with Hodgkin’s Lymphoma Is Related to More Treatment-Induced Leucopenia and Warrants a More Individualized Therapy.

Beate Klimm, MD, Thorsten Reineke, Heinz Haverkamp, Hans T. Eich, MD, Andreas Josting, MD, Beate Pfistner, PhD, Volker Diehl, MD, Andreas Engert, MD

Blood (2004) 104 (11): 1313.

https://doi.org/10.1182/blood.V104.11.1313.1313

Published: 2004

NARROW

Outcome and Risk Factors of Hodgkin Lymphoma Patients with Relapse or Progression After Autologous Stem Cell Transplant: A Report From the German Hodgkin Study Group (GHSG).

Late Events in Patients with Relapsed or Refractory Hodgkin’s Lymphoma Treated with an Autologous Stem Cell Transplantation.

Prognostic Factors and Treatment Outcome in Lymphocyte Predominant and Classical Hodgkin’s Lymphoma: A Comprehensive Analysis of the German Hodgkin Study Group.

Rituximab Added to an Intensified Salvage Chemotherapy Program Followed by Autologous Stem Cell Transplantation Improve in Relapsed and Refractory Aggressive Non-Hodgkin-Lymphoma.

A New BACOPP Schedule Is Feasible and Effective in Elderly Hodgkin’s Lymphoma Patients - Interim Results of a Multicenter Phase-II Trial of the German Hodgkin Study Group (GHSG).

Outcome of Patients Progressing or Relapsing after Primary Treatment with Two Cycles of Chemotherapy and Radiotherapy for Early Stage (Favorable) Hodgkin’s Disease.

Elderly Patients with Early-Unfavorable Stage Hodgkin’s Disease (HD) Have a Poorer Outcome When Treated with Combined Modality Treatment and Extended Field Radiotherapy (EF): A Retrospective Analysis of the German Hodgkin Study Group.

Cologne High-Dose Sequential Chemotherapy in Relapsed and Refractory Hodgkin Lymphoma - Results of a Large Multicenter Study of the German Hodgkin Lymphoma Study Group (GHSG).

Comparison of Patients (Pts) Characteristic and Treatment Outcomes in Lymphocyte-Predominant (LPHD) and Classical Hodgkin’s Disease (cHD): A Report from the German Hodgkin Lymphoma Study Group (GHSG).

The Superior Prognosis of Female Patients with Hodgkin’s Lymphoma Is Related to More Treatment-Induced Leucopenia and Warrants a More Individualized Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only